Nazin0.005%+0.02%

Nazin 0.005%+0.02% is an over-the-counter (OTC) ophthalmic combination product used for the short-term, symptomatic relief of minor eye redness and irritation. It is not intended to treat the underlying cause of eye redness (such as bacterial infection) and provides temporary symptom relief only.

Established / labeled uses

• Temporary relief of redness of the eye due to minor eye irritation caused by dust, smoke, smog, wind, sun glare, swimming, or prolonged reading/screen use.
• Temporary relief of minor eye irritation and itching caused by pollen, ragweed, grass, animal hair, or dander (allergic-type conjunctival irritation).
• Symptomatic relief of mild, non-infectious conjunctival congestion and watering associated with minor conjunctivitis-type irritation.

Not indicated for

• Treatment of bacterial, viral, or fungal eye infections (it does not treat the underlying infection).
• Use as a substitute for prescribed glaucoma therapy or any prescription ophthalmic treatment.
• Continuous or long-term use for chronic red eye without medical evaluation.

If redness, irritation, or pain persists beyond 72 hours, worsens, or is accompanied by eye pain or vision changes, a physician should be consulted, as this may indicate a condition Nazin 0.005%+0.02% is not intended to treat.

Nazin 0.005%+0.02% is a fixed-dose ophthalmic combination containing two active ingredients:

• Naphazoline (as naphazoline hydrochloride) – an imidazoline-derivative topical ocular decongestant, typically formulated at a low concentration (commonly around 0.01%–0.03%) in over-the-counter eye drop products.
• Zinc sulfate – an ocular astringent, typically formulated at a low concentration (commonly around 0.25%) in over-the-counter eye drop products.

The exact strength and inactive ingredients (e.g., buffers, preservatives such as benzalkonium chloride, lubricating agents) vary by manufacturer and formulation; the product label of the specific pack should always be checked for exact composition.

Nazin 0.005%+0.02% is a topical ophthalmic (eye) preparation available as sterile eye drops. It combines an alpha-adrenergic agonist decongestant (naphazoline) with a mild astringent (zinc sulfate) to relieve the appearance and discomfort of red, minor-irritated eyes.

Nazin 0.005%+0.02% is available without a prescription in most markets and is intended for short-term, as-needed use rather than continuous long-term therapy.

Ophthalmic decongestant–astringent combination; Nazin 0.005%+0.02% belongs to the class of topical ocular vasoconstrictors (imidazoline derivatives) combined with an astringent agent, used in over-the-counter eye redness/irritation relief products.

Mechanism of action

Nazin 0.005%+0.02% combines two complementary mechanisms:

• Naphazoline is a direct-acting alpha-adrenergic (sympathomimetic) agonist. It stimulates alpha-adrenergic receptors in the conjunctival blood vessels, producing local vasoconstriction that reduces conjunctival hyperemia (redness) and mild edema.
• Zinc sulfate acts as a mild astringent. It precipitates surface proteins and helps to clear excess mucus, providing a soothing, mildly antiseptic effect on the irritated ocular surface.

Pharmacokinetics

After topical ocular administration, systemic absorption of naphazoline is normally low but can be clinically significant with overuse, punctal occlusion is not typically practiced by patients, or in young children, where absorption relative to body size is proportionally greater and systemic sympathomimetic/CNS effects have been reported. Onset of decongestant action is rapid (within minutes) and effects are generally short-lived, which is why frequent reapplication is often desired by users — a pattern that itself increases the risk of rebound redness (see Precautions and Warnings).

• Wash hands before use.
• Remove contact lenses before instilling Nazin 0.005%+0.02%, unless directed otherwise by a physician; most formulations are not intended for use with contact lenses in place.
• Tilt the head back, gently pull down the lower eyelid to form a small pocket, and instill the drop(s) without letting the dropper tip touch the eye, eyelid, fingers, or any surface, to avoid contaminating the solution.
• Close the eye gently for 1–2 minutes after instillation; applying light pressure at the inner corner of the eye (near the nose) may reduce systemic absorption.
• Replace the cap tightly after use and do not share the bottle with other people.
• Wait to reinsert contact lenses per the product label or physician's advice (typically at least 15 minutes, if lens use is approved for that product).

Clinically significant interactions with Nazin 0.005%+0.02% are primarily related to its sympathomimetic (naphazoline) component:

• Monoamine oxidase inhibitors (MAOIs): Concurrent or recent use (within 2 weeks) of MAOIs may potentiate the pressor (blood pressure-raising) effects of naphazoline through impaired catecholamine metabolism; concurrent use should be avoided or undertaken only under medical supervision.
• Tricyclic antidepressants and other sympathomimetic agents: Concomitant systemic use may have additive cardiovascular sympathomimetic effects (e.g., increased heart rate, blood pressure); caution is advised.
• Other topical ophthalmic products: Space administration of other eye drops or ointments by at least 5–10 minutes to avoid dilution or washout of Nazin 0.005%+0.02%.

Patients on antihypertensive therapy, beta-blockers, or other cardiovascular medications should use Nazin 0.005%+0.02% with caution and inform their physician, due to the potential for systemic sympathomimetic absorption (see Precautions and Warnings).

Common (local, ocular)

• Transient stinging or burning on instillation
• Temporary blurred vision
• Pupil dilation (mydriasis)
• Increased sensitivity to light (photophobia)
• Dryness or mild irritation of the eye

Uncommon / with overuse

• Rebound conjunctival redness (conjunctivitis medicamentosa) with frequent or prolonged use (see Precautions and Warnings)
• Increased eye pressure in susceptible individuals

Rare (systemic, usually with overdose/misuse or in young children)

• Headache, dizziness, drowsiness or sedation
• Palpitations, changes in heart rate, elevated blood pressure
• Sweating, nausea
• In young children: marked drowsiness/CNS depression, hypothermia, bradycardia, and hypotension have been reported with accidental ingestion or excessive use (see Overdose Effects)

Patients should discontinue Nazin 0.005%+0.02% and seek medical advice if eye pain, vision changes, continued redness/irritation, or signs of an allergic reaction (swelling, rash, itching beyond the treated area) occur.

Pregnancy: There are no well-controlled studies establishing the safety of Nazin 0.005%+0.02% in human pregnancy. Although systemic absorption from topical ocular use is generally low, Nazin 0.005%+0.02% should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. A physician should be consulted before use during pregnancy.

Lactation: It is not known whether the components of Nazin 0.005%+0.02% are excreted in human breast milk in clinically significant amounts. Because many drugs are excreted in breast milk, caution is advised and a physician or pharmacist should be consulted before using Nazin 0.005%+0.02% while breastfeeding.

• Rebound redness: Frequent or prolonged use of Nazin 0.005%+0.02% beyond a few days can cause rebound hyperemia (conjunctivitis medicamentosa), where the eye becomes redder as the decongestant effect wears off, leading to a cycle of overuse. Use should be limited to short-term, as-needed relief.
• Cardiovascular disease, hypertension, hyperthyroidism, diabetes: Because naphazoline can be absorbed systemically and has sympathomimetic activity, patients with these conditions should consult a physician before using Nazin 0.005%+0.02%, as it may raise blood pressure or heart rate.
• Contact lenses: Nazin 0.005%+0.02% is generally not recommended for use while wearing contact lenses; remove lenses before instillation unless a physician advises otherwise.
• Not for infections: Nazin 0.005%+0.02% relieves symptoms only and does not treat underlying bacterial, viral, or fungal eye infections. Do not use if the eye has a discharge that is thick/purulent, or if there is significant pain, as this may indicate a condition requiring different treatment.
• Duration limit: Discontinue and see a physician if redness or irritation persists for more than 72 hours, worsens, or recurs shortly after stopping treatment.
• Contamination: Avoid touching the dropper tip to any surface, including the eye, to prevent contaminating the solution and causing eye infection.
• Children: Keep out of reach of children; accidental ingestion can cause serious systemic effects (see Overdose Effects and Use in Special Populations).

Accidental ingestion of Nazin 0.005%+0.02%, particularly by young children, can cause serious systemic effects because of the sympathomimetic (naphazoline) component. Reported symptoms of overdose/ingestion include marked drowsiness or sedation, CNS (central nervous system) depression, low body temperature (hypothermia), slow heart rate (bradycardia), low blood pressure, sweating, and in severe cases, coma.

If Nazin 0.005%+0.02% is swallowed or significant overdose/misuse is suspected, seek immediate medical attention or contact a poison control center / emergency services right away. Do not attempt home treatment for a suspected ingestion; take the product container with you or have the label information available when seeking help.

Store at room temperature (below 30°C), away from light and moisture. Keep the bottle tightly closed when not in use. Keep out of reach of children. Discard the bottle if the solution becomes discolored or cloudy, and discard any opened bottle after the period specified on the label (commonly within 1–3 months of opening) even if solution remains.

Pediatric use

Use of Nazin 0.005%+0.02% in children under 6 years of age is not recommended without physician guidance; safety and effective dosing have not been well established in this age group, and young children are at greater risk of systemic sympathomimetic effects from accidental ingestion or overuse (see Pediatric Uses and Overdose Effects).

Elderly

No specific dose adjustment is established for elderly patients; however, elderly patients are more likely to have cardiovascular disease, hypertension, or narrow-angle glaucoma, so Nazin 0.005%+0.02% should be used with caution and only after appropriate assessment in this group (see Contraindications and Precautions and Warnings).

Hepatic and renal impairment

No specific dose adjustment data exist for hepatic or renal impairment, as systemic exposure from correctly used topical ocular Nazin 0.005%+0.02% is expected to be minimal; nonetheless, caution is reasonable given the sympathomimetic component.

Nazin 0.005%+0.02% is intended for short-term, intermittent, as-needed use only — not for continuous daily use over extended periods. If symptoms of eye redness or irritation persist for more than 72 hours despite use, worsen, or recur soon after stopping the drops, discontinue Nazin 0.005%+0.02% and consult a physician, as continued use beyond this period increases the risk of rebound redness and may mask an underlying condition needing different treatment.

Nazin 0.005%+0.02% falls under the drug classes: ophthalmic decongestants (topical ocular vasoconstrictors), imidazoline-derivative alpha-adrenergic agonists (naphazoline component), and ophthalmic astringents (zinc sulfate component).

Nazin 0.005%+0.02% works through two complementary local actions on the eye: naphazoline, an alpha-adrenergic agonist, constricts small conjunctival blood vessels to reduce redness, while zinc sulfate acts as an astringent that precipitates surface proteins and helps clear mucus, giving a soothing effect on irritated conjunctival tissue.

Nazin 0.005%+0.02% is generally labeled for use in adults and children 6 years of age and older, at 1–2 drops in the affected eye(s) up to 4 times daily as needed. For children under 6 years, safety and efficacy have not been established, and a physician should be consulted before use, since young children absorb proportionally more of the sympathomimetic (naphazoline) component relative to body weight and are more susceptible to systemic effects such as CNS depression, bradycardia, and hypothermia if the product is ingested or overused. Nazin 0.005%+0.02% should always be kept out of the reach of children to prevent accidental ingestion.